HSBC Holdings
CRNX icon

HSBC Holdings’s Crinetics Pharmaceuticals CRNX Stock Holding History

HSBC Holdings’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-210,821
Closed -$8.78M – 2980
2025
Q3 		$8.78M Buy
210,821
+203,624
+2,829% +$6.51M ﹤0.01% 976
2025
Q2 		$209K Sell
7,197
-6,292
-47% -$194K ﹤0.01% 2650
2025
Q1 		$439K Buy
13,489
+937
+7% +$35K ﹤0.01% 2153
2024
Q4 		$645K Buy
12,552
+4,788
+62% +$268K ﹤0.01% 2028
2024
Q3 		$398K Sell
7,764
-3,184
-29% -$164K ﹤0.01% 2140
2024
Q2 		$478K Buy
10,948
+4,072
+59% +$188K ﹤0.01% 1990
2024
Q1 		$322K Buy
+6,876
New +$269K ﹤0.01% 2405
2023
Q3 		– Sell
-12,327
Closed -$225K – 2736
2023
Q2 		$225K Buy
+12,327
New +$246K ﹤0.01% 2275
2021
Q1 		– Sell
-17,868
Closed -$252K – 2793
2020
Q4 		$252K Buy
17,868
+1,791
+11% +$24.9K ﹤0.01% 2688
2020
Q3 		$249K Buy
16,077
+4,598
+40% +$70.3K ﹤0.01% 2353
2020
Q2 		$201K Buy
+11,479
New +$196K ﹤0.01% 2364
2019
Q4 		– Sell
-12,197
Closed -$183K – 3064
2019
Q3 		$183K Buy
+12,197
New +$237K ﹤0.01% 2889

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HSBC Holdings's CRNX Position: Q4 2025 in Review

HSBC Holdings sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 210,821 shares — an estimated $8.78M sold.

HSBC Holdings first reported a position in CRNX in Q3 2019 and held it in 12 quarters. The position peaked at $8.78M in Q3 2025. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • HSBC Holdings reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • HSBC Holdings sold 210,821 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $8.78M.
  • HSBC Holdings first reported a position in Crinetics Pharmaceuticals in Q3 2019 and held it in 12 quarters.
  • HSBC Holdings's Crinetics Pharmaceuticals position peaked at $8.78M in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on HSBC Holdings's 13F filing for Q4 2025, filed 6 Mar 2026.